Pharmaceutical Law Violations in Korea: What Pharma Companies & Distributors Must Review Now
Why You Need to Review Compliance Now
Regulatory scrutiny over pharmaceutical rebate practices in Korea is intensifying. What is notable is that enforcement is no longer limited to individual misconduct but is increasingly focused on the overall transaction structure of a company. Authorities are examining how sales, contracts, and financial flows are designed and whether those structures, in substance, incentivize prescriptions or product adoption.
Pharmaceutical companies and distributors operating in Korea are subject not only to the Pharmaceutical Affairs Act, but also to the Medical Service Act, national health insurance regulations, and fair trade laws. This layered regulatory framework creates a situation where a single transaction can raise multiple legal issues at once.
In this environment, superficial compliance systems or loosely implemented internal controls can become a risk factor rather than a safeguard. If internal processes appear formal but lack substance, they may be interpreted as evidence of systematic or intentional violations. As a result, companies must move beyond field-level caution and instead reassess their entire structure, including contracts, expense allocation, and internal approval systems, from a regulatory perspective.
Key Risk Areas for B2B Pharmaceutical Businesses
One of the most common issues arises from rebate structures tied to prescription volume or product adoption. Even when benefits are provided under the label of marketing support, education, or promotional activities, they may still be treated as illegal rebates if there is a clear connection to sales performance.
Another major risk involves consulting or marketing agreements that lack substantive deliverables. Payments made as advisory fees, research funding, or academic sponsorships may be questioned if there is no meaningful output such as reports, meeting records, or measurable contributions. In such cases, authorities may view the arrangement as a disguised incentive rather than a legitimate contract.
Additionally, inflated or fictitious expenses present a significant exposure. Creating artificial costs through fabricated service contracts or exaggerated advertising fees to fund rebates can lead not only to pharmaceutical law violations but also to tax-related issues. These cases often trigger broader investigations that combine regulatory enforcement with financial scrutiny.
Legal and Business Consequences
Violations of Korean pharmaceutical regulations can lead to both criminal liability and administrative sanctions. In serious cases, executives and employees may face imprisonment or fines, and the company itself may also be penalized under joint liability provisions. Where misconduct is repeated or structurally embedded, enforcement trends indicate that actual custodial sentences are increasingly being considered.
Administrative measures can have an even more immediate impact on business operations. These may include suspension of sales, significant monetary penalties, and reimbursement or clawback actions under national health insurance rules. Beyond formal sanctions, companies often experience secondary consequences such as loss of business partners, exclusion from procurement opportunities, and deterioration in financial credibility. In practice, these combined effects can threaten the long-term viability of the business.
What Must Be Reviewed Immediately
At this stage, companies should first examine whether their contract and expense structures are genuinely tied to real services and outcomes. Agreements labeled as consulting, services, or academic support must be supported by clear documentation and tangible deliverables. If such arrangements are directly or indirectly linked to prescription or sales performance, they are likely to be scrutinized as potential rebate schemes.
It is equally important to review internal sales processes and approval systems. Companies need to ensure that promotional expenses and support payments are approved based on clear and consistent criteria, and that the decision-making process is fully traceable. If the approval structure cannot be explained or reconstructed, the organization itself may be exposed to allegations of intentional or negligent involvement.
Finally, compliance frameworks must be practical and enforceable. Basic measures such as training sessions or written acknowledgments are no longer sufficient. Effective compliance requires integrating anti-rebate principles into KPI design, incentive structures, and ongoing monitoring systems. The ability to detect irregular transactions early and correct them internally is one of the most important factors in reducing regulatory risk.
The Outcome Is Often Determined Before the Investigation Begins
In many cases, the outcome of pharmaceutical compliance issues in Korea is effectively determined before a formal investigation is initiated. Once authorities conduct a search or begin an inquiry, they rely heavily on existing records, including contract structures, financial flows, and documented internal decisions. At that point, it becomes extremely difficult to modify or reframe the underlying structure.
For this reason, proactive review and restructuring are critical. The key question is whether the company’s current transaction framework can withstand regulatory scrutiny from an objective third-party perspective.
If there is any uncertainty, it is advisable to conduct a compliance review before the risk escalates into an investigation.
